PG — Q1 FY2027 Financial Report Analysis

Procter & Gamble opened fiscal 2027 (its fiscal year runs July to June, so this is the quarter ended September 30, 2026) with net sales up 4% to $23.3 billion, and this time the growth came from selling more product. Organic sales, P&G's measure of sales growth with currency swings and businesses bought or sold stripped out so it shows underlying demand, also rose 4%, built from 2.4 points of higher unit volume, 1.1 points of richer product mix and only 0.4 points of price. That is a sharp turn from fiscal 2026, when volume was flat for the whole year and organic sales were flat in the June quarter.

Profit did not keep pace. Gross margin fell 160 basis points (1.6 percentage points) to 49.8% as commodity costs and spending on product upgrades rose, net earnings attributable to P&G slipped 0.4% to $4.73 billion, and diluted EPS rose 1% to $1.97 only because there were 1.2% fewer shares outstanding. Management kept its full-year earnings guidance even though it now expects a bigger cost headwind than it did in July.

Key figures

Operating margin is the share of each sales dollar left after the costs of making, marketing and running the business, before interest and tax. Core EPS is P&G's adjusted figure; this quarter it excludes only restructuring charges above the company's normal yearly level. The prior-year free cash flow productivity is our own calculation from the release's cash flow statement ($5,408M operating cash flow less $1,200M capital spending, divided by $4,781M net earnings); the release only states the current quarter's 93%.

Where the sales growth came from

Fabric & Home Care, the largest segment at 35% of sales, carried the quarter: units up 4.3%, with both laundry (Fabric Care) and Home Care growing mid-single digits on volume gains in North America and Europe. Pricing there was slightly negative (−0.3%), so this was more product sold, not dearer product.

Beauty grew organic sales 5% with volume, price and mix all contributing: hair care on "innovation-based pricing" (price increases tied to new or upgraded products) in North America and Latin America, personal care on volume in Greater China and Europe, and skin care on a richer mix of premium products. Earnings still fell 1%, the second year in a row that Beauty's sales growth has not reached its bottom line.

Grooming and Health Care are the two segments where growth came from price and mix rather than units. Grooming's volume fell 0.4% while price added 3.5 points; Health Care's volume fell 2.9% while price and mix added 2.8 points each. Both oral care and personal health care (over-the-counter medicines) lost unit volume. Health Care nonetheless posted the biggest earnings gain of any segment (+9%), which is what price-led growth tends to look like in the short run.

Baby, Feminine & Family Care, the only segment with negative organic sales last year, returned to +3%, but it got there partly by cutting prices: price was −1.2%, with lower pricing in North American baby care and "merchandising investments" (promotional spending) in family care. Its earnings fell 4%, the weakest of the five.

What happened to the margin

P&G itemizes the 150-basis-point decline in core gross margin, and it shows where the volume came from:

Two things stand out. Commodity costs (raw materials, energy, transport) went from a 20-basis-point drag for all of fiscal 2026 to 140 basis points in a single quarter. And P&G spent another 140 basis points of margin on "product reinvestments", meaning better products at similar prices, which is part of why consumers bought more units. Tariffs flipped from a 30-basis-point drag in fiscal 2026 to a 50-basis-point help this quarter.

Overhead absorbed most of the gross margin loss. SG&A (selling, general and administrative expense: marketing, salaries and offices) fell 90 basis points to 24.3% of sales, as productivity savings (130 bps) and the leverage of a bigger sales base (100 bps) more than covered 120 bps of reinvestment. Net result: operating income still grew 1.4%, but operating margin fell 70 basis points to 25.5%.

Takeaway: P&G got the thing it was missing all of fiscal 2026 — real volume growth of 2.4% — but paid for it with 140 basis points of gross margin in product reinvestment on top of 140 basis points of commodity inflation. Net earnings were flat; the 1% EPS gain came entirely from buying back shares. The quarter answers the demand question and opens a margin question.

What the headline numbers hide

• EPS growth is a buyback effect. Net earnings attributable to P&G fell 0.4%, while the diluted share count fell 1.2% (2,407.2 million vs 2,436.8 million) after another $1.25 billion of repurchases. That share-count drop is the whole of the 1% EPS gain. Currency-neutral core EPS, which also removes the small (+$0.01) help from exchange rates, was exactly flat at $1.99.
• Below the operating line, three small things all went the wrong way. Interest expense rose 13% to $223M, other non-operating income fell 23% to $207M, and the effective tax rate (tax as a share of pre-tax profit) edged up to 21.0% from 20.8%. Together they turned 1.4% operating income growth into flat pre-tax profit.
• GAAP vs core is a small gap. The only adjustment is $98M pre-tax ($77M after tax, $0.03 per share) of restructuring above P&G's normal level, part of the two-year, roughly $2 billion pre-tax portfolio and productivity plan announced in June 2025, which P&G says was more than half done in fiscal 2026 and finishes this year. Last year's comparable charge was $0.04 per share, so the adjustment does not flatter the growth rate.
• Cash conversion is strong, with help from suppliers. Operating cash flow rose 6.6% to $5.8 billion and free cash flow (operating cash flow less capital spending) was $4.4 billion, 93% of net earnings, above P&G's 85–90% full-year target. Part of that came from paying suppliers later: accounts payable added $1,149M of cash versus $648M a year ago, which more than offset a larger build in receivables (−$589M vs −$305M). Receivables rose 9.3% since June 30 and inventories 3.9%, both faster than 4% sales growth, though a quarter-end vs year-end balance comparison partly reflects seasonality.
• Short-term borrowing jumped. Debt due within one year rose to $17.0 billion from $11.3 billion and cash to $15.4 billion from $9.9 billion, ahead of the $3.8 billion Thorne acquisition that closed on October 1, 2026. That is consistent with management doubling its expected net interest headwind for the year (below).

Guidance: same EPS range, bigger cost hole

Organic sales guidance still includes a 30–50 basis-point drag from brands, product forms and go-to-market arrangements P&G is discontinuing under the restructuring.

The headwind P&G has to absorb grew by $0.23 a share in three months, plus a possibly higher tax rate, and the EPS range did not move. Holding it means the business has to generate that much more profit than P&G planned in July, from productivity, volume or the newly acquired Thorne, while staying inside a 1–3% organic range that a 4% first quarter already sits above.

Did last time's read hold up?

Our fiscal 2026 annual analysis said the thing to watch was "not the EPS line, which buybacks and productivity can largely engineer, but volume and market share," and that the 1–3% organic range needed acceleration from the 0% P&G printed in the June quarter. Volume answered decisively: organic sales jumped to 4% with 2.4% unit growth. The EPS line behaved exactly as we expected, with buybacks producing all of the growth. The earnings release does not report market share, so that half of the question waits for the 10-Q. Our other point, that the guidance "leaves no slack," got sharper: the commodity headwind we flagged at $1 billion is now $1.4 billion.

Our read on the year ahead

The quarter is better than the headline EPS suggests on demand and worse on margins. Volume growth of 2.4% in a category business this size is a real change, and it was broad: Fabric & Home Care, Beauty and Baby, Feminine & Family Care all grew units. But the price of that volume is visible in the margin bridge — 140 bps of product reinvestment and, in baby and family care, price cuts and promotions — and P&G now faces 40% more commodity inflation than it planned.

What to watch in the December quarter: whether gross margin stabilizes once productivity savings from the restructuring (which ends this fiscal year) build up, or keeps running about 150 basis points below the prior year; whether Health Care and Grooming, which grew on price with falling volume, start losing units faster; and how much Thorne adds to sales and to interest cost. With core EPS guidance only about 1.5% higher at the midpoint, the dividend and buyback commitments (over $15 billion combined) remain well covered by cash generation, but earnings growth this year depends on P&G keeping the volume while clawing back margin, two things that pulled in opposite directions this quarter.

Source: P&G's first-quarter fiscal 2027 earnings release (8-K Exhibit 99.1, October 22, 2026). The full 10-Q, with management's discussion, market share and segment detail, has not been filed yet.